9 Sept 2019capital raising announcement▲ Good
A further Wainwright-placed offering at $7.52/share, with warrant coverage reduced to 50% of shares sold -- somewhat improved terms versus the June raise.
Announcements, explained
Each one in plain English, with the numbers worked through for a shareholder.
9 Sept 2019securities registration● Neutral
Arcadia Biosciences, Inc. filed a prospectus supplement for an offering off its existing shelf.
9 Sept 2019substantial holder notice● Neutral
D. E. Shaw & Co., L.L.C, D. E. Shaw & Co., L.P, David E. Shaw disclosed a new substantial Arcadia Biosciences, Inc. shareholding (5.50% of votes).
28 Aug 2019securities registration● Neutral
Arcadia Biosciences, Inc. filed the final prospectus for a registered offering.
21 Aug 2019securities registration● Neutral
Arcadia Biosciences, Inc. amended a filing by which it registered a securities offering with the SEC.
14 Aug 2019quarterly activities report● Neutral
Arcadia Biosciences, Inc. reported quarterly revenue of $203 thousand and net income of $4.2 million for the period ended 2019-06-30.
14 Aug 2019quarterly activities report● Neutral
Arcadia Biosciences, Inc. reported quarterly revenue of $203 thousand and net income of $4.2 million for the period ended 2019-06-30.
9 Aug 2019material agreement▲ GoodMajor
Arcadia formed a new joint venture, Archipelago Ventures Hawaii, with Legacy Ventures Hawaii (50.75%/49.25% split) to develop and commercialize hemp-derived CBD products grown in Hawaii -- diversifying beyond its core ag-biotech licensing business, with both partners committing up to roughly $2.5 million in capital.
26 July 2019securities registration● Neutral
Arcadia Biosciences, Inc. registered a securities offering with the SEC.
14 June 2019capital raising announcement▼ Bad
Another Wainwright-placed offering, 1,489,575 shares at $4.91 -- roughly half the per-share price of a year earlier, reflecting the stock's continued decline.
What it means for a shareholder
1.5m new shares at US$4.91 to raise about US$7.3m. That's 24% dilution: every existing holder's slice gets 24% smaller. If you held US$1,000 of shares (204 at the issue price), your slice goes from 0.00426% to 0.00325% of the company. To keep it you'd need 64 more shares - about US$314 at the issue price.
Create a free account to see this worked out for your own holding.
14 June 2019securities registration● Neutral
Arcadia Biosciences, Inc. filed a prospectus supplement for an offering off its existing shelf.
24 May 2019listing compliance notice▼ BadMajor
A further Nasdaq deficiency notice, this time for Minimum Market Value of Listed Securities falling below $35 million -- the company's fourth distinct Nasdaq compliance issue in three years.
8 May 2019quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $158 thousand and a net loss of $12.6 million for the period ended 2019-03-31.
8 May 2019quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $158 thousand and a net loss of $12.6 million for the period ended 2019-03-31.
14 Feb 2019substantial holder notice● Neutral
CVI Investments, Inc, Heights Capital Management, Inc reported a Arcadia Biosciences, Inc. shareholding of 250,783 shares (4.90% of votes) in a periodic institutional filing.
8 Feb 2019substantial holder notice● Neutral
Mitchell P. Kopin, Daniel B. Asher, Intracoastal Capital LLC reported a Arcadia Biosciences, Inc. shareholding of 372,950 shares (7.20% of votes) in a periodic institutional filing.
5 Feb 2019substantial holder notice● Neutral
Hudson Bay Capital Management LP, Sander Gerber disclosed a new substantial Arcadia Biosciences, Inc. shareholding (9.99% of votes).
27 Dec 2018securities registration● Neutral
Arcadia Biosciences, Inc. registered a securities offering with the SEC.
7 Nov 2018quarterly activities report● Neutral
Arcadia Biosciences, Inc. reported quarterly revenue of $370 thousand and net income of $4.5 million for the period ended 2018-09-30.
7 Nov 2018quarterly activities report● Neutral
Arcadia Biosciences, Inc. reported quarterly revenue of $370 thousand and net income of $4.5 million for the period ended 2018-09-30.
8 Aug 2018quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $436 thousand and a net loss of $6.7 million for the period ended 2018-06-30.
8 Aug 2018quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $436 thousand and a net loss of $6.7 million for the period ended 2018-06-30.
21 June 2018substantial holder notice● Neutral
Mitchell P. Kopin, Daniel B. Asher disclosed a new substantial Arcadia Biosciences, Inc. shareholding (8.70% of votes).
21 June 2018substantial holder notice● Neutral
CVI Investments, Inc, Heights Capital Management, Inc disclosed a new substantial Arcadia Biosciences, Inc. shareholding (7.80% of votes).
14 June 2018capital raising announcement▲ Good
Arcadia raised more capital -- 1,392,345 shares at $9.93 plus matching warrants -- via a shelf takedown, with H.C. Wainwright engaged as placement agent, a relationship that would recur in nearly every subsequent financing.
What it means for a shareholder
1.4m new shares at US$9.93 to raise about US$13.8m. That's 36% dilution: every existing holder's slice gets 36% smaller. If you held US$1,000 of shares (101 at the issue price), your slice goes from 0.00406% to 0.0026% of the company. To keep it you'd need 57 more shares - about US$566 at the issue price.
Create a free account to see this worked out for your own holding.
13 June 2018securities registration● Neutral
Arcadia Biosciences, Inc. filed a prospectus supplement for an offering off its existing shelf.
11 May 2018securities registration● Neutral
Arcadia Biosciences, Inc. registered a securities offering with the SEC using its shelf eligibility.
9 May 2018quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $214 thousand and a net loss of $10.6 million for the period ended 2018-03-31.
9 May 2018quarterly activities report▼ Bad
Arcadia Biosciences, Inc. reported quarterly revenue of $214 thousand and a net loss of $10.6 million for the period ended 2018-03-31.
24 Apr 2018securities registration● Neutral
Arcadia Biosciences, Inc. filed the final prospectus for a registered offering.